Peptides
KPV
What is it?
KPV stands for lysine-proline-valine, the three-amino-acid tail of alpha-melanocyte-stimulating hormone. Researchers are interested in it for inflammation in the gut and skin. It is not an FDA-approved medicine. [1,2]
How might it work?
In cell experiments, KPV enters some intestinal cells through a peptide transporter and reduces inflammatory signaling. In mouse colitis experiments, KPV in drinking water reduced measures of gut inflammation. Those are meaningful early findings, but mouse and cell amounts cannot be translated directly into a human regimen. [1]
Why do people discuss it for gut health?
The proposed appeal is local anti-inflammatory action in the intestine. Other mouse studies have tested special KPV-loaded particles to improve delivery and reported less colitis. Those engineered particles are not the same as an ordinary oral capsule or injection. FDA's 2026 review found no human clinical study or documented human exposure for KPV by any route, so an improvement in human gut symptoms has not yet been measured in a controlled trial. [2,3]
What should you know before considering it?
The human safety picture is unusually thin. Absence of adverse-event reports cannot establish safety when exposure itself has not been characterized. Persistent abdominal pain, bleeding, or suspected inflammatory bowel disease deserves medical evaluation rather than self-treatment. [2]
PRACTITIONER EXAMPLES
How much?
FORM & SCHEDULE
What it refers to
by injection each day in one practice guide
These are reported practices, not human-tested doses. Persistent gut symptoms should be assessed by a clinician.
200–500 mcg — KPV by subcutaneous injection once daily is a practice range quoted by Jay Campbell from a clinician; he separately describes 500 mg per day orally for gut-focused use. These very different amounts and routes should not be combined or treated as equivalent. They are practitioner examples, not human dose-finding results. [4]
Read detailed dosing notes
FDA identified no clinical exposure data from which to establish an effective or safe KPV regimen. [2]
Sources & further reading
- Dalmasso et al. (2008). PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation (opens in a new tab)pubmed.ncbi.nlm.nih.gov
- FDA (2026). KPV-related bulk drug substances briefing (opens in a new tab)www.fda.gov
- Xiao et al. (2017). Orally targeted delivery of KPV in experimental colitis (opens in a new tab)pmc.ncbi.nlm.nih.gov
- Jay Campbell. KPV peptide benefits, side effects and dosage (opens in a new tab)jaycampbell.com